Abstract:Immune checkpoint blockade (ICB) has achieved groundbreaking results in clinical cancer therapy; however, only a subset of patients experience durable benefits. The aim of this study was to explore strategies for predicting tumor responses to optimize the intervention approach using ICB therapy. Methods: We used a bilateral mouse model for proteomics analysis to identify new imaging biomarkers for tumor responses to ICB therapy. A PET radiotracer was synthesized by radiolabeling the identified biomarker-targeting antibody with 124I. The radiotracer was then tested for PET prediction of tumor responses to ICB therapy. Results: We identified galectin-1 (Gal-1), a member of the carbohydrate-binding lectin family, as a potential negative biomarker for ICB efficacy. We established that Gal-1 inhibition promotes a sensitive immune phenotype within the tumor microenvironment (TME) for ICB therapy. To assess the pre-ICB treatment status of the TME, a Gal-1-targeted PET radiotracer, 124I-αGal-1, was developed. PET imaging with 124I-αGal-1 showed the pretreatment immunosuppressive status of the TME before the initiation of therapy, thus enabling the prediction of ICB resistance in advance. Moreover, the use of hydrogel scaffolds loaded with a Gal-1 inhibitor, thiodigalactoside, demonstrated that a single dose of thiodigalactoside-hydrogel significantly potentiated ICB and adoptive cell transfer immunotherapies by remodeling the immunosuppressive TME. Conclusion: Our study underscores the potential of Gal-1-targeted PET imaging as a valuable strategy for early-stage monitoring of tumor responses to ICB therapy. Additionally, Gal-1 inhibition effectively counteracts the immunosuppressive TME, resulting in enhanced immunotherapy efficacy.

Targeting galectins in T cell-based immunotherapy within tumor microenvironment

Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Correction: Targeting LAG-3, TIM-3, and TIGIT for Cancer Immunotherapy

Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Galectins as potential emerging key targets in different types of leukemia

Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy

Improving cancer immunotherapy in prostate cancer by modulating T cell function through targeting the galectin-1

Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy

Antibody-based Cancer Immunotherapy by Targeting Regulatory T Cells

Comprehensive characterization of early-programmed tumor microenvironment by tumor-associated macrophages reveals galectin-1 as an immune modulatory target in breast cancer

Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives

Immunology and immunotherapy in gastric cancer

Targeting tumor-infiltrating tregs for improved antitumor responses

Vascular galectins in tumor angiogenesis and cancer immunity